share_log

TG Therapeutics | 8-K: ® TG Therapeutics Reports Third Quarter 2024 Financial Results and Raises BRIUMVI (ublituximab-xiiy) Full Year Revenue Guidance

SEC ·  Nov 4, 2024 20:24
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.